These firms are in the forefront of the cancer wars, and their stocks should deliver healthy gains.
Medical science hasn’t yet won the war on cancer, but it is scoring important victories in battles against many forms of the dreaded disease. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks.
Companies such as Medivation have fueled the renewed lure of striking it rich from novel cancer treatments. With Xtandi—its breakthrough treatment for prostate cancer—riding high, plus promising new drugs for breast cancer and blood cancers in development, the company was the object of a bidding war in 2016. It culminated last September with drug giant Pfizer (symbol PFE) paying $14 billion for Medivation, or $81.50 per share—38 times the stock’s level at its 2010 low.
In February, Japan’s Takeda Pharmaceuticals (TKPYY) paid $5.2 billion for Ariad Pharmaceuticals (ARIA), which is developing drugs that target certain solid tumors. The buyout price was 75% above Ariad’s market value before the deal was announced.
Plenty of volatility. Biotech shares had led the bull market overall, with a New York Stock Exchange–sponsored index of 30 biotech issues soaring 723% from early 2009 to mid 2015. But the stocks then dived 42% by February 2016, in part because of a political backlash against high drug prices.
That backlash remains a long-term threat to the industry’s profit potential, and it continues to weigh on the stocks. Despite a rebound since early 2016, the NYSE biotech index is still down 20% from its 2015 peak. But that could also mean opportunity.
Denne historien er fra June 2017-utgaven av Kiplinger's Personal Finance.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra June 2017-utgaven av Kiplinger's Personal Finance.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
MAKING A DIFFERENCE IN THE LIVES OF DISABLED VETERANS
He suffered grave injuries in the line of duty. Now he helps other veterans who have disabilities.
DO YOU NEED UMBRELLA INSURANCE?
A policy can protect you from financially devastating events.
Navigating Finances as a Blended Family
Money matters can get complicated when two families unite. Planning is key.
BREAKING UP WITH YOUR BROKER
Be aware of these challenges when you move your money to a new home.
CHOOSE A MEDICARE PLAN THAT'S RIGHT FOR YOU
Consider your health care needs over the long term as you weigh costs and coverage.
Keep Faith in These Stocks
IN 1997, I coined the phrase “faith-based investing.” It has nothing to do with religion or with picking stocks at random.
OUR ESG PICKS ARE THRIVING
Despite an ongoing backlash, our favorite stocks and funds focused on environmental, social and corporate governance issues had a good year overall.
MONEY MANNERS FOR THE MODERN AGE
The customs for splitting a restaurant check, purchasing a wedding gift, tipping and more have evolved. These guidelines can help.
ELECTION 2024: POLITICS AND YOUR PORTFOLIO
Who wins the White House matters—but only at the margins when it comes to your investments.
YOUR GUIDE TO OPEN ENROLLMENT
With health care costs on the rise, it’s critical to select a plan that fits your needs at the right price.